Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0KN1U
|
|||
| Former ID |
DIB013725
|
|||
| Drug Name |
Myo-inositol hexaphosphate
|
|||
| Synonyms |
Phytic acid; 83-86-3; Phytate; Fytic acid; Inositol hexaphosphate; Alkalovert; myo-Inositol hexaphosphate; myo-inositol hexakisphosphate; Alkovert; Phytine; Acidum fyticum; Acide fytique; Acido fitico; myo-Inositol, hexakis(dihydrogen phosphate); myo-Inosistol hexakisphosphate; inositol hexakisphosphate; Inositol 1,2,3,4,5,6-hexakisphosphate; CCRIS 4513; UNII-7IGF0S7R8I; Saure des phytins [German]; Saeure des phytins; Acidum fyticum [INN-Latin]; Acido fitico [INN-Spanish]; Acide fytique [INN-French]; Inosithexaphosphorsaure; Phytate; SNF-03; SNF-04; SNF-471; SNF-472; SNF-571; SNF-671; Calcium metabolism modulator (transdermal patch formulation, cardiovascular calcifications), Sanifit Laboratoris SL; InsP6 (transdermal patch formulation, cardiovascular calcifications), Sanifit Laboratoris SL; Phytate (intravenous formulation, cardiovascular calcifications), Sanifit Laboratoris SL; Phytate (tablet formulation, osteoporosis), Sanifit Laboratoris SL; Phytate (transdermal patch formulation, cardiovascular calcifications), Sanifit Laboratoris SL; Calcium metabolism modulator (subcutaneous/injectable formulation, cardiovascular calcifications), Sanifit Laboratoris SL; Myo-inositol hexakisphosphate (transdermal patchformulation, cardiovascular calcifications), Sanifit Laboratoris SL; Myo-inositol hexaphosphate (intravenous formulation, cardiovascular calcifications), Sanifit Laboratoris SL; Myo-inositol hexaphosphate (tablet formulation, osteoporosis), Sanifit Laboratoris SL; Myo-inositol hexaphosphate (transdermal patch formulation, cardiovascular calcifications), Sanifit Laboratoris SL; Phytate (transdermal/patch formulation, renal calcium lithiasis), Sanifit Laboratoris SL; SNF-471 (transdermal patch, cardiovascular calcification), Sanifit; SNF-571 (transdermal patch, renal calcium lithiasis), Sanifit; InsP6, (transdermal/patch formulation, renal calcium lithiasis), Sanifit Laboratoris SL; Myo-inositol hexaphosphate (transdermal/patch formulation, renal calcium lithiasis), Sanfit Laboratoris SL; RP-3000
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cardiovascular disease [ICD-11: BA00-BE2Z; ICD-10: I00-I99] | Phase 2/3 | [1] | |
| Gastroesophageal reflux disease [ICD-11: DA22.Z] | Investigative | [2] | ||
| Company |
Sanifit Laboratoris SL
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C6H18O24P6
|
|||
| Canonical SMILES |
C1(C(C(C(C(C1OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O
|
|||
| InChI |
1S/C6H18O24P6/c7-31(8,9)25-1-2(26-32(10,11)12)4(28-34(16,17)18)6(30-36(22,23)24)5(29-35(19,20)21)3(1)27-33(13,14)15/h1-6H,(H2,7,8,9)(H2,10,11,12)(H2,13,14,15)(H2,16,17,18)(H2,19,20,21)(H2,22,23,24)
|
|||
| InChIKey |
IMQLKJBTEOYOSI-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 83-86-3
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:17401
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01000233) Value of Oral Phytate (InsP6) in the Prevention of Progression of the Cardiovascular Calcifications. U.S. National Institutes of Health. | |||
| REF 2 | The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.